
Haider Bin Khaled, MD, discusses real-world outcomes of caplacizumab in iTTP
The study evaluated the safety profile and hospital resource utilization of caplacizumab in a largely geriatric patient cohort. Researchers compared patients who received caplacizumab alongside standard plasmapheresis and rituximab against those who received plasmapheresis and rituximab alone.





